With eight products in its pipeline, Ophthotech is aiming to lead the gene therapy front for retinal diseases, Glenn P. Sblendorio, MBA, the company’s CEO and president, said at the 37th annual J.P. Morgan Healthcare Conference in San Francisco.
“Our goal as a company is to become a leader in developing gene therapies and novel therapeutics for the treatment of retinal diseases,” he said.
Over the past year, Ophthotech has expended its pipeline from one product to eight and has added industry experts to its board, including former Santen CEO (Read more...)
Uncategorized